← All trials
NCT05562024
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2022
- Primary completion
- Dec 18, 2025
- Completion date
- Feb 18, 2039
- First posted
- Sep 30, 2022
- Last posted
- Nov 3, 2022
- Enrollment
- 24
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.Lead sponsor
- Tianjin Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.